Mode
Text Size
Log in / Sign up
N/A Completed N=3,095

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Source: ClinicalTrials.gov NCT00936208 ↗
Enrolled (actual)
3,095
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Change in Diastolic Blood Pressure From Baseline at Week 24 — -15.3; -18.3 mmHg

Summary

PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Diastolic Blood Pressure From Baseline at Week 24
-15.3; -18.3 —
PRIMARY
Change in Systolic Blood Pressure From Baseline at Week 24
-26.6; -32.8 —
SECONDARY
Framingham Score at Week 24
10.6; 14.2 —
SECONDARY
Change in the Framingham Score From Baseline at Week 24
-5.2; -6.3 —
SECONDARY
International Renal Interest Society (IRIS) II Score at Week 24
30.9; 31.7 —
SECONDARY
Change in the IRIS II Score From Baseline at Week 24
-5.8; -7.0 —
SECONDARY
Change From Baseline in Urinary Microalbuminuria (Urine Dipstick Test Results)
821; 668; 21; 26; 1; 9 —

Eligibility Criteria

Inclusion criteria

  • Male or female
  • Aged 20 to 80 years old.
  • adult with essential hypertension - either newly diagnosed and untreated, or previously treated and uncontrolled
  • Sitting blood pressure: systolic BP > 140 mmHg but 90 mmHg but 55 years (Males), > 65 years (Females), smoking, overweight or obese patients or a combination of above risk factors
  • Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication

Exclusion criteria

  • Patients with contraindications to Telmisartan use (as per the Micardis® Tablets package insert).
  • Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® .
  • Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
  • Patients participating in any other clinical trial.
  • Patients already on Micardis® alone or combination
  • Pregnant females, or females breast feeding.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00936208). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search